JD Health, Xiaohongshu, and Influencer IPs Share Strategies to Unlock the Out-of-Hospital Market Traffic Pool at 2025 VBEF

Sun Yuewu, Chairman of the Committee, China Association for the Promotion of Healthy Development of PharmaceuticalsWe will analyze the policies and product opportunities in the out-of-hospital market,Professor Duan Tao, Shanghai First Maternity and Infant HospitalOn-site unveiling of a multi-million-level IP incubation methodology, while Health Growth Society provides long-termists with a detailed explanation of the Spark Paradigm for healthcare growth.

JD HealthHow to Achieve N-Fold Growth in Pharmaceutical and Medical Device Branding and Operations Based on E-commerceHengxu CapitalInterpreting the Business Growth Logic of Foods for Special Medical Purposes from an Investment Perspective,Fanzhuo GroupandXiuShi BioPharmaceuticalsDecoding the Breakthrough Path for Chinese Medical Aesthetic Materials. Furthermore,Guangzhou BaiyunshanHutchison Health、Huimei Digital Health、Sichuan Zhenghexiang Group、Hua MedicineUnlocking the Growth Secrets of New Business Models and Channels in the Out-of-Hospital Market from Multiple Dimensions.

The Battle for the Out-of-Hospital Market: It’s All About “Traffic.” How Can Pharmaceutical Companies Win the Trillion-Yuan Traffic War in the Out-of-Hospital Market? What Is the Growth Code for Blockbuster Health and Medical Products? How Can the Success of Mega-Blockbusters with Annual Sales Exceeding RMB 1 Billion Be Replicated? Can the Traffic-Wave Creation Tactics of E-commerce Marketing Be Transferred and Duplicated? Where Lie the Boundaries of Health and Medical Content Dissemination?

The one-day conference will be dedicated exclusively toConduct research and discussion centered on the core essential issue of “traffic.”All your questions about “traffic” can be answered at this conference.

This conference,New-channel players such as pharmaceutical e-commerce platforms, MCN agencies, and DTP pharmacies, as well as manufacturers of new out-of-hospital market categories including pharmaceuticals and medical devices, foods for special medical purposes (FSMP), and health productswill come together to accelerate resource collaboration and development in the out-of-hospital market.

Furthermore, VCBeat VBEF concurrently hosts a series of N+ activities, including closed-door government-enterprise meetings, premium asset promotion conferences, and innovative product launch events. By adopting an integrated “exhibition + forum + transaction” model, it facilitates deep connections between high-quality assets and global capital, the local industrial chain, and end-user medical institutions, thereby helping China’s innovative healthcare and pharmaceutical assets bridge the gap from “innovation capability” to “productive capacity.”

The exhibition facilitates diverse matchmaking:2025 VBEF Special Exhibition Area DesignCentral Stage (Thematic Roadshows, Product Launches), Innovative Product Showcase (Product Demos, Case Studies)、Innovative Assets Poster Exhibition (Top 100 Investment Landscape, Resource Matchmaking)Three Major Value Domains: Accelerating the Value Fission of High-Quality Assets in China’s Healthcare and Pharmaceutical Innovation Through Innovative Models and Efficient Mechanisms.

Forum Decoding Trends:2 Main Forums, 4 Featured Forums, and 20+ Thematic Forums comprehensively cover the hot sectors of high-quality innovative assets in China’s healthcare and pharmaceutical industries. Over 300 industry leaders, academicians, experts, and corporate executives discuss growth poles in China’s healthcare industry, precisely identifying growth drivers for high-quality assets.

High-Efficiency Trading Scenarios:Exhibiting companies can engage directly with international buyers, overseas distributors, and supply chain partners. Through on-site negotiations and demand-matching sessions, they can swiftly secure business opportunities in cross-border cooperation, technology introduction, and product distribution, thereby facilitating the integration of China’s high-quality innovative medical and pharmaceutical assets into the global industrial chain.